gutflix
GI learning, personalised

Summary

POST-MARKET USE OF TEDUGLUTIDE IN A LARGE COHORT OF ADULTS WITH SHORT BOWEL SYNDROME: EVOLUTION AND OUTCOMES

Lore Billiauws

UEG Week Copenhagen 2023 | Poster

Small Intestine & Nutrition

October 15, 2023

A French expert center retrospectively analyzed teduglutide implementation in 331 short bowel syndrome with chronic intestinal failure patients between 2015 and 2020, finding that 16.9% initiated treatment with variable uptake between prevalent and incident populations.

KEY POINTS

- Treatment with teduglutide allowed a median 60% reduction in parenteral support volume, with significantly greater reduction in incident patients compared to prevalent patients.
- Among the cohort, 27.9% of prevalent patients and 8.0% of incident patients initiated teduglutide, with 18.2% of non-treated patients deemed unsuitable for non-medical reasons including compliance concerns and patient refusal.
- Long-term retention rates were 82% at 2 years, 67% at 3 years, and 64% at 5 years, which the authors attribute to careful patient selection.
- The authors conclude that the findings suggest a potential benefit of early treatment and confirm long-term efficacy of teduglutide in real-world practice.
- This study is relevant for gastroenterologists managing short bowel syndrome patients and healthcare systems evaluating teduglutide implementation strategies.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/b09904c0-743c-11ee-a1be-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.